These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 28043094)

  • 21. Kinetics of Hepatitis B Surface Antigen Level in Chronic Hepatitis B Patients who Achieved Hepatitis B Surface Antigen Loss during Pegylated Interferon Alpha-2a Treatment.
    Li MH; Zhang L; Qu XJ; Lu Y; Shen G; Wu SL; Chang M; Liu RY; Hu LP; Li ZZ; Hua WH; Song SJ; Xie Y
    Chin Med J (Engl); 2017 Mar; 130(5):559-565. PubMed ID: 28229987
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Successful treatment of chronic hepatitis B and D with pegylated-interferon plus entecavir.
    Chen GY; Su TH; Kao JH
    J Formos Med Assoc; 2015 Nov; 114(11):1140-1. PubMed ID: 23791143
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Reply to: "Serum HBsAg kinetics in clinical prediction".
    Brunetto M; Cornberg M; Chan HL
    J Hepatol; 2017 Jul; 67(1):193-194. PubMed ID: 28315711
    [No Abstract]   [Full Text] [Related]  

  • 24. Sequential combination therapy with pegylated interferon leads to loss of hepatitis B surface antigen and hepatitis B e antigen (HBeAg) seroconversion in HBeAg-positive chronic hepatitis B patients receiving long-term entecavir treatment.
    Li GJ; Yu YQ; Chen SL; Fan P; Shao LY; Chen JZ; Li CS; Yi B; Chen WC; Xie SY; Mao XN; Zou HH; Zhang WH
    Antimicrob Agents Chemother; 2015 Jul; 59(7):4121-8. PubMed ID: 25941216
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Focus.
    Shouval D
    J Hepatol; 2013 Dec; 59(6):1151-2. PubMed ID: 24021425
    [No Abstract]   [Full Text] [Related]  

  • 26. [Clinical analysis of seroconversion of HBsAg in chronic hepatitis B patients treated with PegIFN alpha-2a].
    Yang F; Wu XF; Li XH; Wei N
    Zhonghua Gan Zang Bing Za Zhi; 2009 Dec; 17(12):950-1. PubMed ID: 20038343
    [No Abstract]   [Full Text] [Related]  

  • 27. Treatment outcome in patients of hepatitis B with hepatitis D: experience of 4 years at a tertiary care centre in Pakistan.
    Zuberi BF; Quraishy MS; Afsar S; Akhtar N; Kumar A; Dodani SK
    J Coll Physicians Surg Pak; 2007 Jun; 17(6):320-2. PubMed ID: 17623577
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The Predictive Value of Baseline HBsAg Level and Early Response for HBsAg Loss in Patients with HBeAg-positive Chronic Hepatitis B during Pegylated Interferon Alpha-2a Treatment.
    Li MH; Zhang L; Qu XJ; Lu Y; Shen G; Li ZZ; Wu SL; Liu RY; Chang M; Hu LP; Hua WH; Song SJ; Wan G; Xie Y
    Biomed Environ Sci; 2017 Mar; 30(3):177-184. PubMed ID: 28427487
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Current management of delta hepatitis.
    Rizzetto M
    Liver Int; 2013 Feb; 33 Suppl 1():195-7. PubMed ID: 23286865
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Hepatitis B surface antigen quantification: why and how to use it in 2011 - a core group report.
    Chan HL; Thompson A; Martinot-Peignoux M; Piratvisuth T; Cornberg M; Brunetto MR; Tillmann HL; Kao JH; Jia JD; Wedemeyer H; Locarnini S; Janssen HL; Marcellin P
    J Hepatol; 2011 Nov; 55(5):1121-31. PubMed ID: 21718667
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Early serum hepatitis B virus large surface protein level: a stronger predictor of virological response to peginterferon alfa-2a than that to entecavir in HBeAg-positive patients with chronic hepatitis B.
    Zhu X; Gong Q; Yu D; Zhang D; Gu L; Han Y; Chen J; Zhang Y; Zhang X
    J Clin Virol; 2013 Aug; 57(4):318-22. PubMed ID: 23639294
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Optimized HBsAg titer monitoring improves interferon therapy in patients with chronic hepatitis delta.
    Ouzan D; Pénaranda G; Joly H; Halfon P
    J Hepatol; 2013 Jun; 58(6):1258-9. PubMed ID: 23318602
    [No Abstract]   [Full Text] [Related]  

  • 33. [The levels of HBsAg can predict the efficacy of peglated interferon-alpha 2a combined with adefovir dipivoxil, in HBeAg-positive chronic hepatitis B patients].
    Sun HX; Cao H; Zhang K; Yang XA; Li G; Xu QH
    Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi; 2011 Apr; 25(2):132-4. PubMed ID: 21863639
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A response-guided approach based on HBsAg kinetics may identify patients with the greatest chance of success.
    Halfon P; Pénaranda G; Ouzan D
    J Hepatol; 2015 Jan; 62(1):238. PubMed ID: 25308177
    [No Abstract]   [Full Text] [Related]  

  • 35. Pegylated-interferon alpha therapy for treatment-experienced chronic hepatitis B patients.
    Yeh ML; Peng CY; Dai CY; Lai HC; Huang CF; Hsieh MY; Huang JF; Chen SC; Lin ZY; Yu ML; Chuang WL
    PLoS One; 2015; 10(4):e0122259. PubMed ID: 25835020
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Prediction of off-treatment response to lamivudine by serum hepatitis B surface antigen quantification in hepatitis B e antigen-negative patients.
    Chan HL; Wong GL; Chim AM; Chan HY; Chu SH; Wong VW
    Antivir Ther; 2011; 16(8):1249-57. PubMed ID: 22155906
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Prediction of sustained response to peginterferon alfa-2b for hepatitis B e antigen-positive chronic hepatitis B using on-treatment hepatitis B surface antigen decline.
    Sonneveld MJ; Rijckborst V; Boucher CA; Hansen BE; Janssen HL
    Hepatology; 2010 Oct; 52(4):1251-7. PubMed ID: 20830787
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Screening for serum biomarkers in patients with chronic hepatitis B with hepatitis B surface antigen seroclearance, following pegylated interferon alpha therapy.
    Wang Z; Li X; Shi C; Zhang M; Chen R; Wu W; Hou Q; Ke W; Fan T; Wen Z; Hao X; Qu N
    Mol Med Rep; 2015 Jan; 11(1):427-33. PubMed ID: 25324041
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Interferon therapy of chronic hepatitis B.
    Brunetto MR; Bonino F
    Intervirology; 2014; 57(3-4):163-70. PubMed ID: 25034484
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Quantification of serum hepatitis B surface antigen: is it useful for the management of chronic hepatitis B?
    Janssen HL; Sonneveld MJ; Brunetto MR
    Gut; 2012 May; 61(5):641-5. PubMed ID: 22180061
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.